Errata: Vol. 63, No. RR-5

Weekly

December 12, 2014 / 63(49);1182-1182

In the MMWR Recommendations and Reports "Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)," an error occurred on page 5. The last sentence of the first full paragraph should read, "Among these six cancers, approximately 21,300 were attributable to HPV16/18 (7,900 [37%] among men and 13,400 [63%] among women) (Table 2)."

In Table 2 on page 6, the average annual numbers of cancers attributable to HPV 16/18 were incorrect. Following is the corrected table:

TABLE 2. Average annual number and percentage of cancer cases attributable to human papillomavirus and to HPV 16 and HPV 18, by anatomic site and sex — United States, 2006–2010.
Anatomic site	Average no. of cancers per year in sites where HPV is often found (HPV-associated cancers)*			Cancers attributable to any HPV				Cancers attributable to HPV 16/18
	Male	Female	Both sexes	%	Average no.†			%	Average no.†
	Male	Female	Both sexes	%	Male	Female	Both sexes	%	Male	Female	Both sexes
Cervix	0	11,422	11,422	91§	0	10,400	10,400	67	0	7,700	7,700
Anus	1,549	2,821	4,370	91	1,400	2,600	4,000	79	1,200	2,200	3,400
Oropharynx	9,974	2,443	12,417	72	7,200	1,800	9,000	62	6,200	1,500	7,700
Penis	1,048	0	1,048	63	700	0	700	48	500	0	500
Vagina	0	735	735	75	0	600	600	57	0	400	400
Vulva	0	3,168	3,168	69	0	2,200	2,200	49	0	1,600	1,600
Total	12,571	20,589	33,160		9,300	17,600	26,900		7,900	13,400	21,300
Abbreviation: HPV = human papillomavirus. * Sources: Data come from population-based cancer registries that participate in the National Program of Cancer Registries and/or the Surveillance, Epidemiology, and End Results Program, and meet criteria for high data quality. Cancer Registry Data are from all states meeting USCS publication criteria (http://www.cdc.gov/cancer/npcr/uscs/technical_notes/criteria.htm) for all years 2006–2010 and cover approximately 94.8% of the US population. In order to determine those cancers most likely to be HPV-associated, the following additional criteria were applied to the NPCR/SEER data: all cancers were microscopically confirmed; cervical cancers were limited by histology to carcinomas only (ICD-O-3 histology codes 8010–8671, 8940–8941); all other cancer sites were limited by histology to squamous cell carcinomas only (ICD-O-3 histology codes 8050–8084,8120-8131); oropharyngeal cancers were defined as having the following ICD-O-3 site codes: 19, 24, 28, 90–91, 98–99, 102, 108–109, 140, 142, and 148. † The estimated number of HPV-attributable or HPV 16/18-attributable cancers was calculated by multiplying the HPV-associated cancer counts by the percentage of each cancer attributable to HPV or HPV16/18. Estimates rounded to the nearest 100. § Although HPV is accepted to be a necessary factor in the causal pathway to invasive cervical cancer, HPV is not always detected in tumor specimens from women who receive a diagnosis of invasive cervical cancer due to a variety of reasons, including misclassification of tissue specimens as cervix, quality of tissue specimens, assay sensitivity, and a small proportion of HPV-negative, cervical cancers.